Trial Profile
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2023
Price :
$35
*
At a glance
- Drugs Nibrozetone (Primary) ; Nivolumab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Acronyms PRIMETIME
- Sponsors EpicentRx
- 15 Mar 2023 According to an EpicentRx media release, data (n=12) from this study were presented at the international journal, Frontiers in Immunology.
- 15 Mar 2023 Results presented in an EpicentRx media release.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology